• 6.3 Million patient years

    Creon® offers 6.3 million patient years' experience in managing PEI and a solid foundation of successful clinical trials providing a wealth of data.5

  • Creon®’s Unique Mode of Action

    Creon®’s optimally sized minimicrospheres and unique enteric coating ensure your PEI patients get the right dose.

  • What Does Untreated PEI Mean for Your Patients?

    • Reduced quality of life1
    • Higher risk of cardiovascular events2,3
    • Increased morbidity and mortality1
  • Creon® Dosing for Effective PEI Treatment

    With a wide range of strengths – from Creon® Micro (5,000) to Creon® 25,000 –  Creon® enables effective dosing to meet all your patients’ needs.

Pert treatment goals

Follow the Link  Refresh your knowledge

Effective Creon® Dosing

Follow the Link  Get up to date

Resources for practice & patient

Follow the Link  Find support


  1. Ockenga J. HPB 2009; 11(3): 11-5.
  2. Domínguez-Muñoz JE et al. J Gastroenterol Hepatol. 2011; 26(Suppl2): 12-6.
  3. Toouli J et al. Med J Aust. 2010; 193(8): 461-7.
  4. Data on file, RM27550; October 2014.
  5. Data on file, RM27559; July 2015.

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?